Your web browser is out of date! We recommend you update your browser to receive the best possible browsing experience.
Pre-order your Brochure

You can't afford to get your pricing strategy wrong.


The route to reimbursement for your innovative drugs is a minefield for the modern pharma company. 

Success no longer means the greatest profitability. It means the fairest and most sustainable balance. 

Recent headlines have shown us what can go wrong with a pricing model that leaves the patient in the cold - but in an uncertain healthcare landscape ahead of the presidential elections, it's also imperative that pharma makes the money it needs to keep innovating. 

This event has been designed to get you through this minefield. 

For two days immediately following the election, we will be in the perfect place to find, create and deliver value according to the new political climate - and so pharma, payers, providers and ultimately patients can benefit.

Of course, it all starts with good leadership, and good evidence - the two pillars of RWE & Market Access USA 2016, now in its 6th year. 

  • Market Access 2.0: Draw on multi-disciplinary talent to build an access strategy for every stage of the value chain
  • Prepare for the future of healthcare: Discuss the potentials of the post-election healthcare landscape and ensure a robust approach to any eventuality
  • Patient-centric profitability: Get the right reimbursement whilst keeping patients at the forefront of your access plans
  • Invest in outcomes: Learn how pharma is effectively using RWE to break down barriers to access

Pre-order the detailed event brochure

Complete speaker line-up • Program for all tracks & sessions • Audience breakdown

Snapshot of our 2016 presenters

Peter Speyer


Global Head of RWE Solutions

Brande Ellis


Sr. Director – Center of Expertise, Global Patient Outcomes & RWE,

Robert Popovian


Sr. Director of US Government Relations

Stacy Woeppel


Deputy Director, Regulatory Affairs

Tamar Thompson

Bristol-Myers Squibb

Director, Federal Agency Payment,

Edmond S. Malka


Head of Epidemiology & Real World Data Sciences

Melinda Hanisch


Director, Research Dissemination, Medical Policy & Quality Research – Center for Observational and Real World Evidenc

Strike the right 'value balance'


Providing real value for all stakeholders means whittling down costs and improving patient outcomes. In other words, doing more with less.

To achieve this, a collaborative effort is required. Satisfying regulatory bodies and payers, and delivering value-based evidence that paves the way for patient access, means better communication and understanding between all parties is a priority. And that includes competing pharma brands!

Meanwhile, as we strive to meet the demands of payers looking for cost-effective products, R&D budgets are skyrocketing. Drugs that deliver optimal patient outcomes, satisfy payers and still bring pharma a healthy ROI are becoming harder to create and develop.

Achieving patient access for a tried, tested and approved drug begins with robust clinical trials and rigorously analyzed real life evidence. But there must also be a strong business case for finding disease solutions. RWE is fast proving itself to be worth the extra expense incurred upfront, sharpening a brand's competitive edge throughout the lifecycle. 

If any of this resonates with your vision for the future of your business - you have a duty to attend this meeting! 

Pre-order the detailed event brochure

Complete speaker line-up • Program for all tracks & sessions • Audience breakdown

New for 2016:

    Combining data analysis with strategic delivery, you'll hear insights directly from the originators (health systems, providers), the operators (HEOR, data analytics) and the strategists (market access and pricing) of real world evidence. Nowhere else will you get insights from the entire suite of stakeholders – all in one place.
  • 50+ SESSIONS:
    Across three different tracks, case studies and presentations reveal best-practice insights on how to demonstrate drug value for market access with real life data sets
    Interactive roundtables are involving the key stakeholders directly; IDNs and payers will be at the driving seat of the conversation.
    Executive leadership talks uncover how data-driven evidence is changing the pharmaceutical industry

Industry Testimonials: What our Delegates are saying

Pre-order the detailed event brochure

Complete speaker line-up • Program for all tracks & sessions • Audience breakdown

Our Leadership in Real World Evidence:

  • eyeforpharma RWE is the No. 1 annual meeting-place for data, HEOR and market access executives in the United States, Japan and Europe
  • A collaborative conference: Every session, every discussion, and every question we ask comes directly from our network of thousands of biopharma executives
  • A strictly senior pharma audience: The only industry event where you spend two days learning and networking among senior-level peers. You won’t get lost in an expo, or sit among thousands of academic researchers – this is the industry meeting place
  • Tailored to your priorities: The 3-track approach means you can shape your two days to fit the issues that matter most to you and your company. Pick and choose from Market Access, Data & Analytics or Outcomes Research sessions
84% of our attendees call our sessions “essential” to their future success
98% rated the program very well run
94% of our attendees say that will likely return next year

Got a question? Get in touch below!

Aidan Brain

Aidan Brain

VP Market Access | eyeforpharma


UK: +44 (0)207 375 7513

USA Toll Free: +1 800 814 3459 Extn: 7513

Ulrich Neumann

Ulrich Neumann

US Managing Director | eyeforpharma


Phone: 201 204 1688

Pre-order the detailed event brochure

Complete speaker line-up • Program for all tracks & sessions • Audience breakdown